Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Hao Wu
Boston Children's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
SMOC Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Wu has a financial interest in and co-founded SMOC Therapeutics (“SMOC” or “Company”), a Company that intends to develop a platform for drug discovery in the area of inflammation. The subject grant involves NLRP3 proteins. The research has previously been unrelated to the Company. Although Dr. Wu’s work is distinct from the Company, in that Dr. Wu pursues structures and functions of these proteins, while the company is pursuing therapeutics for various diseases, the outcome of Dr. Wu’s research may have the potential to indirectly benefit the company. In addition, Dr. Wu also proposed to screen for small molecule inhibitors in her lab and independent of the company. However if proprietary small molecule inhibitors are identified in her lab, it is possible that SMOC Therapeutics (or other companies) may be interested in licensing them.
Mechanistic Elucidation of Inflammasome Assembly and Regulation
Engagement of the inflammasome pathways in appropriate physiological contexts is important for pathogen recognition and initiates protective immune responses. However, the complexity of this pathway also renders itself susceptible to interruption and dysregulation, leading to its association with many human diseases, such as autoinflammatory diseases, and autoimmune diseases. Understanding this pathway at the molecular level would contribute to both health and disease.
Filed on June 10, 2019.
Tell us what you know about Hao Wu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Hao Wu filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Hao Wu | Boston Children's Hospital | Conflict of Interest | SMOC Therapeutics | $80,000 - $99,999 |
| Hao Wu | Boston Children's Hospital | Conflict of Interest | SMOC Therapeutics | $80,000 - $99,999 |
| Hao Wu | Boston Children's Hospital | Conflict of Interest | SMOC Therapeutics | $0 - $4,999 |
| Hao Wu | Boston Children's Hospital | Conflict of Interest | SMOC Therapeutics | $0 - $4,999 |
| Hao Wu | Boston Children's Hospital | Conflict of Interest | SMOC Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.